Recursive Adaptation - Addiction Medicine and Policy

Home
CASPR.org
Archive
About
CASPR is funding a VA study on GLP-1s and opioid use in veterans
Our first collaboration with the Department of Veterans Affairs.
 • 
Nicholas Reville
Hiring: Intellectual Property Researcher
We are seeking a motivated Intellectual Property Researcher to join us on a part-time or contract basis.
 • 
Lindsay Holden
New study: GLP-1s reduce alcohol hospitalizations
Plus: Novo shortages, EMS refusal, CASPR news, and wonderful anecdotes.
 • 
Nicholas Reville
Hiring: Development Director
The Development Director will play a critical role in securing and growing funding sources to support CASPR’s mission.
 • 
Lindsay Holden
GLP-1s for Reducing Addiction: Everything you need to know
The science, medicine, patient experiences, provider experiences, policy, and more.
 • 
Nicholas Reville
1
10 charts about how and why we haven't solved addiction (and how we can)
Plus the GLP-1 breakthrough that can change our course.
 • 
Nicholas Reville
GRACE for AUD: proposing GLP-1-based alcohol treatment initiation in the ED
Immediate-access craving relief therapy can provide short-term risk reduction and a bridge to treatment.
 • 
Nicholas Reville
FDA standards for addiction medicine studies are discouraging the development of medications
A shift away from abstinence-only and other binary metrics is overdue.
 • 
Nicholas Reville

October 2024

“On Mounjaro, my daily alcohol cravings are gone. Now I just drink one, 8.4-ounce can of Red Bull a day.”
One patient describes how getting on Mounjaro gave her her freedom back.
 • 
Noah Davis
“There were some dark days”: Why there have been shortages of naltrexone, a key medication for alcohol use disorder
Our reporting reveals we should blame increased demand, brittle supply chains, and the DEA.
 • 
Noah Davis
News updates: can GLP-1s help people get back to work?
Ozempic reduces alzheimer's risk, street medicine with long-acting antipsychotics, methadone treatment retention, more
 • 
Nicholas Reville
1
“It was an immediate obliteration of alcohol and opioid cravings.”
Tirzepatide helped a patient with chronic back pain overcome a cycle of opiate and alcohol overuse.
 • 
Noah Davis
4
© 2024 CASPR
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture